# PHIO (Phio Pharmaceuticals Corp) - SEC EDGAR Financial Statements

> Phio Pharmaceuticals Corp reported $11.32M in total assets and a net loss of $14.67M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/PHIO
- Markdown: https://convexityos.com/fundamentals/PHIO.md
- SEC CIK: 0001533040
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:07 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001533040&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$15.24M | Operating profit |
| Net Income | FY 2025 | -$14.67M | GAAP bottom line |
| Diluted EPS | FY 2025 | -- | Split-adjusted |
| Free Cash Flow | FY 2025 | -$12.40M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $10.61M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | -- | -- | -- | -- | -- | $0 | $21K | $138K | $15K | $19K |
| Research & Development | $4.62M | $3.64M | $6.33M | $7.01M | $8.89M | $3.72M | $4.30M | $4.33M | $5.37M | $5.42M |
| Total Operating Expenses | $9.22M | $7.39M | $10.82M | $11.46M | $13.51M | $8.79M | $9.01M | $7.50M | $14.08M | $9.03M |
| **Operating Income** | -$9.22M | -$7.39M | -$10.82M | -$11.46M | -$13.51M | -$8.79M | -$8.99M | -$7.36M | -$14.06M | -$9.02M |
| **EBITDA** | -$9.22M | -$7.38M | -$10.77M | -$11.39M | -$13.44M | -$8.72M | -$8.92M | -$7.28M | -$13.99M | -$8.96M |
| Income Before Tax | -- | -- | -- | -$11.48M | -$13.29M | -$8.79M | -$8.91M | -$7.36M | -$14.07M | -$8.99M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.62M | $0 |
| **Net Income** | -$8.70M | -$7.15M | -$10.83M | -$11.48M | -$13.29M | -$8.79M | -$8.91M | -$7.36M | -$12.45M | -$8.99M |
| Basic EPS | -$1.45 | -$9.08 | -$46.76 | -$90.91 | -$1,343.11 | -$207.46 | -$2,088.68 | -$341,141.99 | -$32,772.43 | -$97,426.73 |
| **Diluted EPS** | -- | -$9.08 | -$46.76 | -$90.91 | -$1,343.11 | -$207.46 | -$2,088.68 | -$341,141.99 | -$32,772.43 | -$97,426.73 |
| Basic Shares Outstanding | 6.0M | 787.5K | 231.5K | 126.3K | 9.9K | 42.5K | 4.3K | 22 | 380 | 114 |
| Diluted Shares Outstanding | -- | 787.5K | 231.5K | 126.3K | 9.9K | 42.5K | 4.3K | 22 | 380 | 114 |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $3.06M | $3.08M | $2.79M | $1.48M | $1.18M | $1.07M | $886K | $985K |
| Total Operating Expenses | $4.27M | $4.27M | $4.17M | $2.53M | $2.50M | $2.31M | $1.87M | $1.67M |
| **Operating Income** | -$4.27M | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | -$1.87M | -$1.67M |
| **EBITDA** | -$4.27M | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | -$1.87M | -$1.67M |
| Interest Expense | -- | -- | -- | -- | -- | -- | -$125K | -- |
| **Net Income** | -$4.16M | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | -$1.77M | -$1.63M |
| Basic EPS | -$0.36 | -$0.36 | -$0.34 | -- | -$0.44 | -$0.45 | -$0.41 | -- |
| **Diluted EPS** | -- | -- | -- | -- | -- | -$0.45 | -$0.41 | -- |
| Basic Shares Outstanding | 11.7M | 11.6M | 11.6M | -- | 5.5M | 4.8M | 4.3M | -- |
| Diluted Shares Outstanding | -- | -- | -- | -- | -- | 4.8M | 4.3M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $21.03M | $5.38M | $8.49M | $11.78M | $24.06M | $14.24M | $6.93M | $14.88M | $3.58M | $12.91M |
| **Cash & Short-Term Investments** | $21.03M | $5.38M | $8.49M | $11.78M | $24.06M | $14.24M | $6.93M | $14.88M | $3.58M | $12.91M |
| **Total Current Assets** | $21.48M | $5.74M | $9.32M | $12.45M | $24.73M | $15.16M | $7.30M | $15.15M | $3.83M | $13.11M |
| Property, Plant & Equipment, Net | $11K | $2.0K | $6.0K | $183K | $133K | $157K | $210K | $172K | $248K | $114K |
| Other Non-Current Assets | -- | $0 | $3.0K | $24K | $27K | $18K | $18K | $0 | $18K | $27K |
| **Total Non-Current Assets** | $11K | $2.0K | $42K | $368K | $443K | $575K | $739K | $172K | $266K | $291K |
| **Total Assets** | $21.49M | $5.74M | $9.36M | $12.81M | $25.17M | $15.74M | $8.04M | $15.32M | $4.10M | $13.40M |
| Accounts Payable | $435K | $253K | $657K | $779K | $283K | $728K | $809K | $550K | $511K | $917K |
| **Total Current Liabilities** | -- | $1.01M | $1.63M | $1.94M | $3.07M | $2.20M | $1.88M | $1.74M | $2.27M | $2.54M |
| Long-Term Debt | -- | -- | -- | -- | $0 | $231K | $0 | -- | -- | -- |
| **Total Non-Current Liabilities** | -- | $0 | $0 | $35K | $170K | $526K | $411K | $0 | $0 | $0 |
| **Total Liabilities** | $1.34M | $1.01M | $1.63M | $1.97M | $3.24M | $2.72M | $2.29M | $1.74M | $2.27M | $2.54M |
| **Total Debt (incl. Leases)** | -- | -- | $35K | $170K | $295K | $642K | $518K | -- | -- | -- |
| Common Stock | $1.0K | $0 | $0 | $0 | $0 | $1.0K | $1.0K | $0 | $0 | $0 |
| Retained Earnings | -$155.1M | -$146.4M | -$139.2M | -$128.4M | -$116.9M | -$103.6M | -$94.82M | -$85.91M | -$78.55M | -$66.10M |
| **Total Stockholders' Equity** | $20.15M | $4.72M | $7.73M | $10.84M | $21.93M | $13.02M | $5.75M | $13.58M | $1.83M | $10.86M |
| Total Equity | $20.15M | $4.72M | $7.73M | $10.84M | $21.93M | $13.02M | $5.75M | $13.58M | $1.83M | $10.86M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $10.61M | $13.00M | $17.03M | $21.03M | $10.71M | $10.78M | $13.28M | $5.38M |
| **Cash & Short-Term Investments** | $10.61M | $13.00M | $17.03M | $21.03M | $10.71M | $10.78M | $13.28M | $5.38M |
| **Total Current Assets** | $11.31M | $14.30M | $17.40M | $21.48M | $11.49M | $11.29M | $13.44M | $5.74M |
| Property, Plant & Equipment, Net | $7.0K | $9.0K | $10K | $11K | $12K | $7.0K | $4.0K | $2.0K |
| Other Non-Current Assets | -- | -- | -- | -- | -- | -- | -- | $0 |
| **Total Non-Current Assets** | $7.0K | $9.0K | $10K | $11K | $12K | $7.0K | $4.0K | $2.0K |
| **Total Assets** | $11.32M | $14.31M | $17.41M | $21.49M | $11.51M | $11.30M | $13.44M | $5.74M |
| Accounts Payable | $886K | $901K | $260K | $435K | $516K | $235K | $427K | $253K |
| **Total Current Liabilities** | -- | -- | -- | -- | -- | $1.21M | $1.27M | $1.01M |
| **Total Non-Current Liabilities** | -- | -- | -- | -- | -- | $0 | $0 | $0 |
| **Total Liabilities** | $2.70M | $1.71M | $950K | $1.34M | $1.67M | $1.21M | $1.27M | $1.01M |
| Common Stock | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $0 | $0 | $0 |
| Retained Earnings | -$167.4M | -$163.2M | -$159.1M | -$155.1M | -$152.7M | -$150.3M | -$148.1M | -$146.4M |
| **Total Stockholders' Equity** | $8.62M | $12.60M | $16.46M | $20.15M | $9.84M | $10.10M | $12.17M | $4.72M |
| Total Equity | $8.62M | $12.60M | $16.46M | $20.15M | $9.84M | $10.10M | $12.17M | $4.72M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$8.70M | -$7.15M | -$10.83M | -$11.48M | -$13.29M | -$8.79M | -$8.91M | -$7.36M | -$12.45M | -$8.99M |
| Depreciation & Amortization | $3.0K | $2.0K | $56K | $71K | $75K | $72K | $67K | $81K | $70K | $53K |
| Stock-Based Compensation | $481K | $147K | $303K | $414K | $480K | $136K | $300K | $282K | $314K | $756K |
| Change in Payables | $183K | -$404K | -$122K | $496K | -$445K | -$81K | $259K | $39K | -$608K | -$246K |
| **Operating Cash Flow** | -$7.98M | -$7.11M | -$10.75M | -$12.13M | -$11.86M | -$8.80M | -$8.64M | -$7.52M | -$9.51M | -$7.76M |
| Capital Expenditure | -$12K | -$1.0K | -$5.0K | -$121K | -$51K | -$19K | -$72K | -$5.0K | -$203K | -$4.0K |
| **Free Cash Flow** | -$7.99M | -$7.11M | -$10.75M | -$12.25M | -$11.91M | -$8.82M | -$8.72M | -$7.53M | -$9.72M | -$7.76M |
| Sales & Maturities of Investments | -- | -- | -- | -- | -- | -- | -- | -- | -- | $7.50M |
| **Investing Cash Flow** | -$12K | $8.0K | -$5.0K | -$121K | -$51K | -$19K | -$72K | -$5.0K | -$103K | $5.35M |
| Common Stock Issued | $20.60M | $4.00M | $7.45M | -- | -- | $12.09M | $708K | $1.31M | $290K | $10.20M |
| **Financing Cash Flow** | $23.64M | $4.00M | $7.41M | -$26K | $21.72M | $16.13M | $772K | $18.82M | $292K | $10.20M |
| **Net Change in Cash** | $15.65M | -$3.11M | -$3.34M | -$12.28M | $9.81M | $7.31M | -$7.95M | $11.30M | -$9.32M | $7.79M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$4.16M | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | -$1.77M | -$1.63M |
| Depreciation & Amortization | $2.0K | $1.0K | $1.0K | $1.0K | $2.0K | $0 | $0 | $0 |
| Stock-Based Compensation | $285K | $278K | $318K | $274K | $113K | $51K | $43K | $48K |
| Change in Payables | -$15K | $641K | -$175K | -$80K | $281K | -$192K | $174K | $69K |
| **Operating Cash Flow** | -$2.28M | -$4.04M | -$4.00M | -$2.08M | -$2.08M | -$2.54M | -$1.27M | -$1.37M |
| Capital Expenditure | $0 | $0 | $0 | $0 | -$7.0K | -$3.0K | -$2.0K | -$1.0K |
| **Free Cash Flow** | -$2.28M | -$4.04M | -$4.00M | -$2.08M | -$2.09M | -$2.54M | -$1.28M | -$1.37M |
| **Investing Cash Flow** | $0 | $0 | $3.0K | $0 | -$7.0K | -$3.0K | -$2.0K | $8.0K |
| **Financing Cash Flow** | -$107K | $0 | $0 | $12.40M | $2.02M | $40K | $9.17M | $1.35M |
| **Net Change in Cash** | -$2.39M | -$4.04M | -$4.00M | $10.33M | -$70K | -$2.50M | $7.90M | -$8.0K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Operating Margin** | -- | -- | -- | -- | -- | -- | -42795.2% | -5336.2% | -93746.7% | -47447.4% |
| **Net Profit Margin** | -- | -- | -- | -- | -- | -- | -42419.0% | -5333.3% | -83013.3% | -47336.8% |
| Return on Equity (ROE) | -43.2% | -151.4% | -140.1% | -105.9% | -60.6% | -67.6% | -155.0% | -54.2% | -679.3% | -82.9% |
| Return on Assets (ROA) | -40.5% | -124.6% | -115.6% | -89.6% | -52.8% | -55.9% | -110.8% | -48.0% | -303.9% | -67.1% |
| Current Ratio | -- | 5.65x | 5.71x | 6.42x | 8.06x | 6.91x | 3.88x | 8.69x | 1.69x | 5.16x |
| Quick Ratio | -- | 5.30x | 5.20x | 6.08x | 7.84x | 6.49x | 3.69x | 8.53x | 1.58x | 5.08x |
| Debt to Equity | -- | -- | 0.00x | 0.02x | 0.01x | 0.05x | 0.09x | -- | -- | -- |
| **Revenue Growth (YoY)** | -- | -- | -- | -- | -- | -100.0% | -84.8% | +820.0% | -21.1% | -44.1% |
| 5Y Revenue / Share Growth | -- | -- | -- | -- | -- | -100.0% | -- | +172.0% | -96.9% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -170.2% | -102.4% | -66.4% | -43.2% | -80.8% | -70.2% | -55.6% | -151.4% |
| Return on Assets (ROA) | -129.6% | -90.2% | -62.8% | -40.5% | -69.1% | -62.7% | -50.3% | -124.6% |
| Current Ratio | -- | -- | -- | -- | -- | 9.36x | 10.58x | 5.65x |
| Quick Ratio | -- | -- | -- | -- | -- | 8.93x | 10.46x | 5.30x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
